Related references
Note: Only part of the references are listed.Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML)
Bernard Tawfik et al.
ANNALS OF HEMATOLOGY (2014)
Decitabine in patients with newly diagnosed and relapsed acute myeloid leukemia
Ellen K. Ritchie et al.
LEUKEMIA & LYMPHOMA (2013)
Elacytarabine has single-agent activity in patients ?with advanced acute myeloid leukaemia
Susan O'Brien et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy
Michael Luebbert et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2012)
Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
Auke D. Adema et al.
INVESTIGATIONAL NEW DRUGS (2012)
Multicenter, Randomized, Open-Label, Phase III Trial of Decitabine Versus Patient Choice, With Physician Advice, of Either Supportive Care or Low-Dose Cytarabine for the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia
Hagop M. Kantarjian et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies
F. J. Giles et al.
LEUKEMIA (2012)
Therapeutic Advances in Acute Myeloid Leukemia
Alan Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Outcome of patients with acute myelogenous leukemia after second salvage therapy
F Giles et al.
CANCER (2005)
Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia
BD Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation
G Jackson et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
Share Paper
